Company Overview and News

86
DXTR / Dextera Surgical Inc. FORM S-8 POS

2018-06-07 sec.gov
crdc20180606_s8pos.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM S-8 POS

2018-06-07 sec.gov
crdc20180606_s8pos.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM S-8 POS

2018-06-07 sec.gov
crdc20180606_s8pos.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM S-8 POS

2018-06-07 sec.gov
crdc20180606_s8pos.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM S-8 POS

2018-06-07 sec.gov
crdc20180606_s8pos.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM S-8 POS

2018-06-07 sec.gov
crdc20180606_s8pos.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM S-8 POS

2018-06-07 sec.gov
crdc20180606_s8pos.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM S-8 POS

2018-06-07 sec.gov
crdc20180606_s8pos.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM S-8 POS

2018-06-07 sec.gov
crdc20180606_s8pos.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM S-8 POS

2018-06-07 sec.gov
crdc20180606_s8pos.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM POS AM

2018-06-07 sec.gov
crdc20180606_posam.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM POS AM

2018-06-07 sec.gov
crdc20180606_posam.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM POS AM

2018-06-07 sec.gov
crdc20180606_posam.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM POS AM

2018-06-07 sec.gov
crdc20180606_posam.htm
DXTR

86
DXTR / Dextera Surgical Inc. FORM POS AM

2018-06-07 sec.gov
crdc20180606_posam.htm
DXTR

DXTR : Dextera Surgical Stock Analysis and Research Report

2017-10-16 - Asif

Dextera Surgical is commercializing and developing the MicroCutter 5/80TM stapler based on its proprietary ‘‘staple-on-a-strip’’ technology intended for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its proprietary ‘‘staple-on-a-strip’’ technology enables it to develop products with innovative features such as consistent staple forms, significantly reduced tool shaft diameter and increased articulation. Together these advances in stapler design enable surgeons to perform procedures on a broader array of patients and to develop procedural methods previously unattainable with existing products in the market. The MicroCutter 5/80, which is currently commercially available, is a cartridge-based stapler device with a 5 millimeter shaft diameter, 80 degrees of articulation, and a 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union, or EU, for a broader range of specified indications of use. Dextera esti...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 14141R101